Featured Research

from universities, journals, and other organizations

Designer Chemical Offers Alzheimer's Hope

Date:
August 3, 2001
Source:
University Of Illinois At Chicago
Summary:
Researchers at the University of Illinois at Chicago have designed and synthesized highly potent inhibitor compounds that could lead to an effective treatment for Alzheimer’s disease. The work was reported in the American Chemical Society’s Journal of Medicinal Chemistry.

Researchers at the University of Illinois at Chicago have designed and synthesized highly potent inhibitor compounds that could lead to an effective treatment for Alzheimer’s disease. The work was reported in the American Chemical Society’s Journal of Medicinal Chemistry.

Related Articles


Arun Ghosh, professor of chemistry, led the UIC research team in collaboration with Jordan Tang, head of the Protein Studies department at the Oklahoma Medical Research Foundation in Oklahoma City.

In earlier work, Ghosh and Tang designed an inhibitor that blocks the action of one of two protein-cutting enzymes, called proteases, thought to be responsible for Alzheimer’s disease. This enzyme, called memapsin 2, severs a longer protein in the brain called amyloid precursor protein, or APP, to produce beta-amyloid, which accumulates in the brain and forms plaques that lead to the development of Alzheimer’s disease.

“This enzyme is probably the most exciting target for an Alzheimer’s drug,” said Ghosh.

Tang discovered the precise location where memapsin 2 cuts APP. Subsequently, Tang and Ghosh demonstrated that a model inhibitor compound attracts memapsin 2 and keeps it from cutting APP — a promising way to halt accumulation of beta-amyloid in the brain. That inhibitor was reported in the Journal of the American Chemical Society last year and was shown to be effective in test tube experiments.

The research team knew that while useful as a model, the inhibitor would not be effective in drug therapy. “That was a preliminary inhibitor,” said Ghosh. “It’s a big one, containing eight peptides — a size that is inconceivable to be a drug candidate.”

Ghosh and his team set out to reduce the molecule’s size in an effort to increase its potential as a drug candidate.

“Peptide-like compounds never make useful drugs because they’re metabolically unstable, they’re insoluble and, perhaps the biggest problem in Alzheimer’s patients, they’re hard to deliver in the human brain,” Ghosh said. The molecule has to be small enough to cross what’s called the blood-brain barrier. “Peptide-like molecules are not very good at penetrating this barrier. Our ultimate goal is to deliver a totally non-peptide inhibitor,” he said.

The current paper describes a new generation of inhibitors designed and tested in the laboratory. These new inhibitors are still potent yet substantially smaller, comparable in size to HIV protease inhibitor drugs now being prescribed.

“Designing a smaller, more potent inhibitor is an important step in the development of an effective treatment for Alzheimer’s patients,” said Tang.

The research is supported by grants from the National Institutes of Health.

The Alzheimer’s Association reports about 4 million Americans now suffer from the disease. It predicts that number will grow as the population ages, unless a cure or prevention is found. Current treatments provide only symptomatic relief.


Story Source:

The above story is based on materials provided by University Of Illinois At Chicago. Note: Materials may be edited for content and length.


Cite This Page:

University Of Illinois At Chicago. "Designer Chemical Offers Alzheimer's Hope." ScienceDaily. ScienceDaily, 3 August 2001. <www.sciencedaily.com/releases/2001/08/010803083854.htm>.
University Of Illinois At Chicago. (2001, August 3). Designer Chemical Offers Alzheimer's Hope. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2001/08/010803083854.htm
University Of Illinois At Chicago. "Designer Chemical Offers Alzheimer's Hope." ScienceDaily. www.sciencedaily.com/releases/2001/08/010803083854.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Mind & Brain News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Former NFL Players Donate Brains to Science

Former NFL Players Donate Brains to Science

Reuters - US Online Video (Mar. 3, 2015) Super Bowl champions Sidney Rice and Steve Weatherford donate their brains, post-mortem, to scientific research into repetitive brain trauma. Jillian Kitchener reports. Video provided by Reuters
Powered by NewsLook.com
Alzheimer's Protein Plaque Found In 20-Year-Olds

Alzheimer's Protein Plaque Found In 20-Year-Olds

Newsy (Mar. 3, 2015) Researchers found an abnormal protein associated with Alzheimer&apos;s disease in the brains of 20-year-olds. Video provided by Newsy
Powered by NewsLook.com
This Nasal Treatment Could Help Ease Migraine Pain

This Nasal Treatment Could Help Ease Migraine Pain

Newsy (Mar. 2, 2015) Researchers gave lidocaine to 112 patients, and about 88 percent of the subjects said they needed less migraine-relief medicine the next day. Video provided by Newsy
Powered by NewsLook.com
How Facebook Use Can Lead To Depression

How Facebook Use Can Lead To Depression

Newsy (Mar. 1, 2015) Margaret Duffy of the University of Missouri talks about her study on the social network and the envy and depression that Facebook use can cause. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins